Asia Pacific
Refine Search
Biotechnology
East Coast, USA-based biotech incubator Flagship Pioneering is expanding into the Asia-Pacific, with a new regional hub in Singapore. 8 November 2023
Pharmaceutical
Privately-held Italian drugmaker Menarini and USA/China-based SciClone Pharmaceuticals have entered into an exclusive sub-licensing agreement to develop and commercialize Orserdu (elacestrant) in China. 8 November 2023
Biotechnology
South Korea’s Chong Kun Dang Pharmaceutical's stock soared 26.1% to end at 128,000 won on Monday, on news of a deal with Swiss pharma giant Novartis. 7 November 2023
Biotechnology
A collaboration between Senti Biosciences and Celest Therapeutics will see the latter gain rights to develop SENTI-301A in China. 7 November 2023
Pharmaceutical
Shares Japanese drugmaker Sosei Heptares rose 4% to 1,390 yen today, after it announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of daridorexant (ACT-541468). 31 October 2023
Biotechnology
Indian drugmaker Intas Pharmaceuticals has inked an exclusive deal with Shanghai Henlius Biotech for the development and commercialization of serplulimab in Europe and India. 30 October 2023
Pharmaceutical
The Global Health Innovative Technology (GHIT) Fund and United Nations-backed Medicines Patent have signed a Memorandum of Understanding (MOU) to strengthen their collaboration to improve access to medicines. 30 October 2023
Biotechnology
German life sciences and pharma firm Merck KGaA today announced a strategic collaboration with China’s Jiangsu Hengrui Pharmaceuticals. 30 October 2023
Pharmaceutical
Tokyo-headquartered pharma major Takeda has announced results for the first half of its fiscal year, which in Japan runs from April 1 to September 1. 27 October 2023
Pharmaceutical
Japanese drugmaker Otsuka today announced positive results of two, six-week, Phase III clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD). 27 October 2023
Pharmaceutical
China’s National Medical Products Administration (NMPA) has approved ViiV Healthcare’s Vocabria (cabotegravir injection) used in combination with Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection. 26 October 2023
Biotechnology
Shares of Sino-American biotech LianBio shot up 120% to $3.06 in early US trading today, on the news of an agreement with US pharm major Bristol Myers Squibb. 24 October 2023
Pharmaceutical
Medicines regulator Health Canada has approved Orgovyx (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer, Japanese drugmaker Sumitomo Pharma announced. 24 October 2023
article
The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Byooviz (ranibizumab-nuna) as a biosimilar product interchangeable with Lucentis (ranibizumab). 24 October 2023
Biotechnology
Chinese drugmaker Sichuan Kelun Pharmaceutical on Monday revealed that Merck & Co was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials. 24 October 2023
Biotechnology
The TROPION-Lung01 Phase III trial has yielded positive data for datopotamab deruxtecan (Dato-DXd), an investigational TROP2-directed antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo and AstraZeneca. 23 October 2023
Biotechnology
Shanghai-based gene therapy company Belief BioMed (BBM) has out-licensed certain rights for the commercialization of its hemophilia candidate, BBM-H901. 23 October 2023
Biotechnology
At the annual congress of the European Society for Medical Oncology (ESMO), Seagen and Astellas Pharma have presented detailed data from the Phase III EV-302 study. 23 October 2023
Biotechnology
Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC). 23 October 2023
Biotechnology
UK pharma major GSK has entered into an exclusive license agreement with Chinese biopharma firm Hansoh Pharma for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in Phase I (NCT05263479) clinical trials in China. 21 October 2023
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze